Ultrasound increases graft tissue cell viability
Ultrasound can help tissue grafts to survive and thrive following surgery, according to research in the Journal of Tissue Engineering.
Ultrasound can help tissue grafts to survive and thrive following surgery, according to research in the Journal of Tissue Engineering. Ultrasound can improve cell viability by increasing cellular movement and tissue blood flow.
The study found that mouse muscle cells stimulated with low-intensity ultrasound showed greater cell numbers and better viability than controls. Researchers used adipose cells cultured from tummy tucks as well as mouse muscle cells.
Over a six-day period the test cells were treated with low-intensity ultrasound at 30 mW/cm2 for short bursts of three or 10 minutes (J Tissue Eng 2010;doi:10.4061/2010/973530).
It was the first time preliminary evidence showed that low-intensity ultrasound can influence the viability of the cultured adipose cells in an in vitro organ culture model, the researchers said. Adipose tissue treated with low-intensity ultrasound showed significantly increased metabolic activity, and had fewer markers for tissue damage.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
